Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 11/20 | 0.45 |
| ▸ | HTR1A | P08908 | 9/20 | 0.45 |
| ▸ | DRD3 | P35462 | 9/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.44 |
| ▸ | HTR2A | P28223 | 10/20 | 0.44 |
| ▸ | HTR7 | P34969 | 9/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HRH1 | P35367 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506508 | 0.95 | PIK3CD (0.59) | PIK3CDPIK3CBALKDRD2HTR1A | |
| SCHEMBL5250208 | 0.91 | PIK3CD (0.55) | PIK3CDPIK3CBALKDRD2HTR1A | |
| SCHEMBL4503114 | 0.89 | PIK3CD (0.57) | PIK3CDPIK3CBALKDRD2HTR1A | |
| SCHEMBL4505982 | 0.86 | PIK3CD (0.62) | PIK3CDPIK3CBALKPOLB | |
| SCHEMBL16674768 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3CBALK | |
| SCHEMBL4505188 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CBALK | |
| SCHEMBL4499425 | 0.83 | ALK (0.49) | PIK3CDPIK3CBALKDRD2HTR1A | |
| SCHEMBL15068911 | 0.83 | PIK3CD (0.58) | PIK3CDPIK3CBALK | |
| Hydrochloric Acid SCHEMBL15069133 | 0.82 | PIK3CD (0.62) | PIK3CDPIK3CBALK | |
| SCHEMBL15069039 | 0.81 | PIK3CD (0.59) | PIK3CDPIK3CBALKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1483262-B1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | PIK3CD 4159/4885PIK3CB 2934/4885ALK 4394/4885 |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | PIK3CD 3763/4885PIK3CB 3181/4885ALK 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.